BLUTH BIO INDUSTRIES
  • BLUTH BIO INDUSTRIES
  • TEAM
  • Technologies
    • Therapeutics >
      • SOPHOROLIPIDS FOR THE TREATMENT OF ASTHMA
      • RECIPROCAL SERUM/PLASMA EXCHANGE FOR TREATMENT OF CANCER
      • PANCREATITIS ASSOCIATED PROTEINS (PAP) FOR TREATMENT OF PANCREATITIS
      • REGENERATION (REG) PROTEINS FOR THE TREATMENT OF DIABETES
      • STEM CELL THERAPY FOR DIABETES
      • IMMUNEX – RECOMBINANT HUMAN IgGFc FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    • Diagnostics >
      • BIOMARKER (BLOOD TEST) DEVELOPMENT AND COMMERCIALIZATION PLATFORM
      • BLOOD TEST FOR DETECTION OF PANCREATIC CANCER
    • Devices >
      • Pheonix TM needle
      • Scratchless Scope TM
      • Bottle Buddy TM
    • Services >
      • Bluth Bio Consulting LLC
      • Publication and Grant Review Services
      • Business of Healthcare
      • Medical Martial Arts
  • News
  • SELECT PUBLICATIONS
  • CONTACT
  • Relationships
SOPHOROLIPIDS FOR TREATMENT OF ASTHMA

Background: sophorolipids are microbially derived glycolipids which we have shown to possess anti-inflammatory effects in experimental sepsis. We have recently applied sophorolipids to other inflammatory diseases such as asthma. 

Asthma market:

Ø      Asthma affects 10-40% of the population worldwide.

Ø      ~3M children, 7M adults in USA alone

Ø      incidence increasing over the past 10 years

Ø      Leading chronic illness in children in USA

Ø      Enormous economic and social concern for healthcare system

Ø      ~$162M/ year hospital costs

Ø      Asthma therapies - $7B in 2002 (USA) and increasing

Ø      80% prophylactic therapy sales

Preclinical Data: Mice induced with an ovalbumin (OVA) based asthma model showed decreased IgE-anti OVA antibodies in lung bronchoalveolar lavage (BAL) fluid with sophorolipid treatment in addition to decreased lung inflammation (histology). Mechanisms of action include downregulation of anti-inflammatory cytokines and modulation of adhesion molecules, nitric oxide, and TLR among others. As these sophorolipids can produce selective derivatives with differential effects – sophorolipids present a novel anti-inflammatory treatment. Preliminary toxicity has been demonstrated at >150x therapeutic /effective doses

IP: Sophorlolipids for use in asthma and atopic diseases – Dr. Bluth (acquired license, forming new entity), patent filed/pending;

Sophorolipids for use in cancer (Drs Bluth and Gross), patent filed/pending

Sophorolipids for use in sepsis – R&D with BioMedica pharma 

 

References:

1. Bluth MH, Kandil E, Mueller CM, Shah V, Lin YY, Zhang H, Dresner L, Lempert L, Nowakowski M, Gross R, Schulze R, Zenilman ME. Sophorolipids block lethal effects of septic shock in rats using a cecal ligation and puncture model of experimental sepsis. Critical Care Medicine 2006;34:188-195.

2. Hardin R, Pierre J, Schulze R, Mueller CM, Fu S, Wallner S, Stanek A, Shah V, Gross R, Weedon J, Nowakowski M, Zenilman M, Bluth MH. Sophorolipids improve sepsis survival: Effects of dosing and derivatives Journal of Surgical Research 2007;142:314-9.


3. Fu S, Wallner S, Bowne W, Zenilman ME, Gross R, Bluth MH. Sophorolipids and their derivatives are lethal against human pancreatic cancer cells. Journal of Surgical Research 2008;148:77-82. 4. Sleiman JN, Kohlhoff SA, Roblin PM, Wallner S, Gross R, Hammerschlag MA, Zenilman ME, Bluth MH. Antimicrobial activity of sophorolipids. Annals of Clinical and Laboratory Science 2009;39:60-63.

Proudly powered by Weebly